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Abstract: 
 Chronic Traumatic Encephalopathy (CTE) is a neuropathological disease that develops 
years after experiencing repetitive traumatic brain injuries. In recent years, this disease has 
been gaining recognition from professional, college, and high school teams that participate in 
contact sports. The purpose of this paper is to review available information about this 
neurodegenerative disease. Only limited published experiments are available on this disease. 
Research on CTE has been limited by the fact that patients can only be diagnosed with the 
disease by a post mortem autopsy. Many experiments were analyzed regarding different CTE 
pathologies, symptoms, and treatments. Articles used in this paper were restricted to only peer 
reviewed pieces. The outcome resulted in credible information about the disease, its 
neuropathy, and signs and symptoms, as well as possible treatment methods of the disease.  
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Main Text: 
 On July 25th, 2017 the New York Times published data from a study that stated 110 out 
of 111 former NFL players had been discovered to have Chronic Traumatic Encephalopathy. 
Chronic Traumatic Encephalopathy, or CTE, is a neurodegenerative disease that has been linked 
to repetitive, mild traumatic brain injuries. CTE has been associated with a variety of symptoms, 
some of them being depression, memory loss, and aggression. Signs and symptoms do not 
appear until years after the initial injury and the disease is very progressive in later years. 
Understanding CTE first takes an understanding of a traumatic brain injury. A traumatic brain 
injury (TBI) is a significant blow or jolt to the head that can cause altered brain function or 
feeling. An example of a mild traumatic brain injury is a concussion. Concussions are a common 
head injury among participants in contact sports or of those who serve in the military. 
According to the University of Pittsburgh’s Brain Trauma Research Center, there are 300,000 
sports-related concussions that occur annually in the U.S. Furthermore, the probability of a 
participant experiencing a concussion per season is as high as 19% (1). This paper will discuss 
and review findings that relate these mild traumatic brain injuries (mTBI) and the pathogenesis 
of CTE. 
CTE hasn’t always been highly acknowledged in past years. It was initially recognized by 
Dr. Martland in boxers who suffered from similar symptoms of being classified as “Punch 
Drunk” (5). Dr. Martland had a career as a medical examiner, forensic pathologist, and teacher 
in New Jersey and New York (24). Later, Dr. Millspaugh, a naval medical officer, introduced the 
term “dementia pugilistica,” in 1937, to describe these same symptoms (6). It wasn’t until 1949, 
however, that the term “chronic traumatic encephalopathy” was suggested by Dr. Critchley, 
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world renowned neurologist, and then changed to “chronic progressive traumatic 
encephalopathy of boxers” in 1957 (13,14,15). These sub-concussive hits being suffered by 
boxers were soon recognized in other contact sport participants and serving military members. 
All of these sports or activities could result in collisions or concussive blows to the skull that 
would possibly result in a mild traumatic brain injury (mTBI). 
Clinical Presentation: 
 Previously, brain injuries could only be diagnosed by the patients’ symptom description, 
which presented 8-10 years after experiencing the mTBI. Symptoms of CTE can include 
headaches, rapid mood swings, impulsive aggression, increased irritability, aggression, memory 
loss, varying levels of depression, and, in some cases, gait abnormalities. One of the most 
severe symptoms can be suicidal thoughts and actions (16).  
 Diagnosing and researching a brain disease or injury such as CTE was historically difficult 
to do because the only way to see the brain was post mortem. Although the histological 
techniques varied, the most common pathological findings were cerebral atrophy, neuronal 
loss, gliosis and argyrophilic neurofibrillary tangles (2). Fortunately, the way we view the brain 
and possible brain injuries has advanced dramatically over recent years. X-Rays, CT scans, and 
MRI’s are now used to take images of the brain, and PET scans can even show functions of the 
brain.  
 Pathogenesis:  
Tau: 
 Tau is an abundant protein found in neurons that associates with the stabilization of 
microtubules and axonal transport (Figure 1) (29). In CTE, specifically, it presents itself in 
abundance in a unique pattern of neurofibrillary tangles, classified as a taupathy. A taupathy is 
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any neurodegenerative disorder characterized by abnormally hyper-phosphorylated tau that 
has misfolded into insoluble aggregates known as neurofibrillary tangles (NFT) (29,2,22).  Some 
examples of common taupathies are progressive supranuclear palsy (PSP), corticobasal 
degeneration (CBD), Pick’s disease, and frontotemporal dementias with parkinsonism and 
Alzheimer’s disease (22).  
Figure 1: A brain cell or neuron. The axon of the cell is very long and thin, which makes it the 
weakest point in the cell. Also it is easily damaged during this and can lead to trouble sending 
signals in the brain (41). 
 Once hyper-phosphorylated, tau assumes a tightly folded confirmation this causes an 
increase in susceptibility to aggregation, conformational change, filament assembly, 
polymerization into paired helical filaments, and bundling of paired helical filaments into 
neurofibrillary tangles and neuropil threads (Figure 2) (17). Tau phosphorylation also leads to 
decreased binding with microtubules and lowers overall microtubule stability. The 
accumulation of tau within these neurons causes synaptic dysfunction and, eventually, cell 
death (Gou). Studies have shown an association with mutations of the tau gene that lead to 
dementia and parkinsonism, showing us that a dysfunction of tau proteins is sufficient to cause 
neurodegeneration and dementia (30).  
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Figure 2: A small transport system within the cells is made up of microtubules. Tau protein 
helps stabilize these small tubes in a normal healthy brain. In CTE, tau proteins begin clumping 
to one another and block this transport system (41). 
 Even though all verified cases of CTE have been related to repetitive mTBI, the 
mechanism of neurodegeneration and taupathy are not fully understood (2). Previous studies 
have shown that rapid acceleration-deceleration injuries have been associated with generating 
these neurotoxic tau fragments, but the development of deterioration has yet to be discovered 
(2). Symptoms of CTE normally present themselves later in life, which may be due to the prion-
like mechanism of p-tau. One theory behind CTE being progressive and is that p-tau can spread 
and aggregate in other areas of the brain. This theory has been demonstrated in mouse models 
by injecting areas of their brain with filamentous human Alzheimer’s disease linked taupathy 
proteins and observing their propagation (30). The taupathies expanded from the injection site 
to other distant brain regions connected by synapses. An additional study confirmed tau 
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propagation using a silver staining technique to identify tau in neighboring brain regions of 
hippocampal injected mice (30). The mechanism in which insoluble tau becomes seeded into 
neighboring cells is absorptive endocytosis. This mechanism was demonstrated in a particular 
study demonstrating the uptake of a preformed tau fibril by endocytosis recruits large amounts 
of endogenous tau within the cell to form filamentous tau inclusions (31). 
Lewy Bodies: 
 Lewy bodies are accumulations of the protein alpha-synuclein within neurons of the 
brain (38). These accumulations have been associated with Parkinson’s disease, Alzheimer’s 
disease, and Lewy body disease (18). CTE, being known as a comorbid disease, has spurred 
researchers to begin studying these protein accumulations as a possible cofactor of the disease. 
A recent study sought out a connection between Lewy bodies and CTE within individuals who 
had suffered mTBI. In this study, researchers took a pool of 694 autopsy participants from 3 
distinct brain donation groups and neuro-pathologically evaluated them for neurodegenerative 
diseases (18). Out of the 694 donations, 269 of the participants were recruited from the 
Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) study donation group 
who had a history of some form of contact sport at the professional or amateur level. The other 
groups were from the Boston University’s Alzheimer Disease Center (ADC) (261 participants), 
and from a brain bank of the Farmingham Heart Study (FHS) (164 participants).  In the UNITE 
group, this study completed an extensive repeated head injury (RHI) and sports questionnaire 
to understand the history of all the participants. The next of kin of the FHS group completed an 
identical athletic history assessment. Participants’ exposure to RHI was defined by the total 
number of years a contact sport was played or years of service in the military. Prior to death, 
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the UNITE group participants’ mood, behavior, cognitive, and clinical statuses were evaluated 
by online surveys (18).  
 The neuropathological diagnosis of CTE was made using the National Institute of 
Neurological Disorders (NINDS) consensus criteria that is rated on a scale of I to IV based on 
severity, described later in this paper. A diagnosis of Alzheimer’s diseases (AD) was made based 
of the National Institute of Aging Reagan criteria, which included intermediate or high 
probability. For a participant to be diagnosed with AD, they would have to have sufficient 
pathology to be classified under the intermediate probability. Lewy bodies were assessed with 
a-synuclein immunohistochemistry throughout the brain and rated on a scale of 0 to III. These 
brain regions were viewed by 200x magnification and scored on the following: areas with no 
Lewy bodies were scored 0, 1-2 Lewy bodies were scored “1,” 3-4 Lewy bodies were scored “2,” 
and areas with 5 or more Lewy bodies were scored “3.” 
 Age is a known factor of neurodegenerative pathology and no participants under the 
age of 50 years old were found to have Lewy bodies or AD. This required comparisons with the 
CTE pathology groups to be done with participants who had died at an age older than 50 years 
old. Comparisons were made into four groups based on distributions of the Lewy bodies 
between the pathological subjects. The groups were LBD, CTE-LBD, AD-LBD, and CTE-AD-LBD. 
Participants with CTE-LBD had higher deposition of Lewy bodies in the brainstem and lower 
deposition in the amygdala-predominant compared to AD-LBD. Neocortical deposition of Lewy 
bodies was 53% higher in CTE-AD-LBD than in the other groups followed by CTE-LBD. Also, Lewy 
bodies for the CTE-LBD group were found higher in the limbic system compared to the other 
groups with AD-LBD being the second highest (18). 
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Table 1: Table showing measurements CTE, CTE-LBD, and CTE-AD-LBD groups comparatively 
(18).  
 Key findings of this study were that individuals known to have CTE had an overall lower 
average age of death. It also showed a substantial increase in dementia and parkinsonism’s 
within patients when both CTE and LBD were observed compared to CTE alone. Dementia in 
patients rose 30% from 61.4% (seen in CTE alone) to 91.4% when CTE and LBD were both 
present. Only 19.5% of patients who were diagnosed with CTE alone had parkinsonism’s. 
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Parkinsonism’s in patients who qualified as having both CTE and LBD jumped to 60% (Table 1). 
Although these pools were not equal, there is an obvious association between Lewy bodies 
being present and an increase of these symptoms. The study also showed that individuals who 
had more years of exposure to contact sports were more likely to have neocortical Lewy body 
accumulation. Those who had 8 or more years of exposure of contact sports were 6.24 times 
more likely to be diagnosed with LBD compared to those with 7 or less years of exposure (18). 
Anatomy: 
 
Gross anatomical abnormalities have been observed during autopsies in individuals with 
a pathology currently associated with CTE. These abnormalities are due to neuronal loss caused 
by phosphorylated tau accumulation. Some of these abnormalities include: reduction of total 
brain weight, enlargement of ventricles, atrophy of functional brain structures, cavum septum 
pollicidum, and depigmentation of the locus coeruleus and substantia nigra (2). These 
abnormalities differ between patients depending on when TBI’s occurred. To have proper 
understanding of these abnormalities and possible symptomatic effects they may have on an 
individual, one must first know the basic anatomy of the major parts of the brain affected by 
CTE.  
 The first part, the cerebrum, consists of the right and left hemisphere, which work 
together to control the body. Within each hemisphere are four lobes, named regionally: the 
occipital, temporal, parietal, and frontal lobes. Each lobe hosts specific higher level brain 
functions. The occipital lobes are responsible for processing vision and the temporal lobes 
process memories and relate them to senses. The parietal lobes register temperature, touch, 
and movement, whereas the frontal lobes control movement and cognitive function (Figure 3) 
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(32, 33).  
 
Figure 3: Regional lobes of the cerebrum and their overlying cortices. This figure shows the 
cerebral lobes and cortex regions affected by CTE (32).  
 
 A major part of the cerebrum is the cerebral cortex. The cerebral cortex is the 
outermost surface of the cerebral hemispheres and is known to be the location of where the 
highest functions are carried out. The cerebral cortex consists of ridges, called gyri, and valleys, 
called sulci, that add surface area to the cortex, which increases the amount of gray matter for 
information storage. The cerebral cortex is divided into four regional areas that correspond to 
the cerebrum; they possess specific functions such as learning, remembering, and language and 
sensory processing (32, 33). 
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Figure 4: The limbic system of the brain. This figure shows some of the limbic system 
structures affected by CTE. The mammillary body, hippocampus, amygdala and thalamic region 
(42).  
 Another major area of the brain affected by CTE is the limbic system. A few important 
structures within the limbic system are the amygdala, thalamus, hippocampus, and mammillary 
bodies. These structures are interconnected and control emotions, mood, and learning, as well 
as short and long term memory (Figure 4) (43). Damage to these specific areas from TBI’s could 
help explain the various symptoms seen in individuals with CTE. 
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Figure 5: This shows general abnormalities caused by CTE. Macro and microscopic 
abnormalities between a normal brain (right) and a brain with signs of CTE (right) (46).  
Signs and Symptoms of CTE: 
Upwards of 90% of TBI’s are classified under what is commonly known as a concussion 
and the symptoms associated with these concussions are usually resolved in two weeks or less 
(8). Individuals who have suffered mTBI and whose symptoms last longer than three months 
may be diagnosed with post concussive syndrome. The symptoms known to be associated with 
post concussive syndrome are varying in severity by subject, including memory problems, 
irritability and other personality changes, sensitivity to light and noise, sleep disturbances, 
depression and other psychological problems, and loss of smell and taste. (9). Multiple 
brain injuries, or concussions, can lead to a higher prevalence of post-concussive symptoms and 
into the neuropathological disease we know as CTE.  
Depression: 
 Depression is one of the most common symptoms of CTE and is seen more in individuals 
who suffer a TBI than in the general population (8).  A history of concussion is associated with 
3.3-fold greater risk for a diagnosis of depression in adolescents as well as a 2-fold increase in 
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the elderly (8). Besides single injury risk, the risk for developing depression is greatly increased 
by the number of concussions sustained by an individual. The relative risk of developing 
depression increases from 1.5 to 3 when individuals report less than 3 versus 3 or 
more concussions (9).  
 Depression treatment responsiveness is inconsistent the majority of the time, and even 
more so for those who suffer from TBI’s (7).  A patient having a history of substance abuse, 
psychosocial factors, and mood disorders may contribute to the risk of developing depression 
following TBI (8). This is why, without a complete understanding of the pathophysiological 
mechanism(s) that lead to depression following TBI, targeted disease-modifying therapies 
cannot be developed (7). There is no individual mechanism currently identified as the cause of 
depression after TBI, but accumulating evidence has shown that inflammatory pathways may 
contribute to its development (48). Knowing that inflammation can persist long after TBI, we 
can then look at the association between the inflammation caused by the TBI and depression 
following (22). A few studies have shown a possible link between increased pro-inflammatory 
biomarkers in cerebral spinal fluids (CSF) following a TBI and increased odds of developing 
depression (43). 
Cytokine Regulation: 
  Cytokines are a category of signaling proteins that act by binding to specific receptors. 
Cytokines can be seen acting on cells that release them via autocrine action, cell to cell signaling 
in local tissue via paracrine action, or long distance signaling via endocrine action. Cytokines are 
usually produced in a cascade producing other cytokines that can work synergistically or 
antagonistically (26). Cytokines are usually linked to the immune system where they are 
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released for defense against pathogens. The cytokines focused on here promote inflammation 
when released. In a normal body, cytokines are produced in small levels and can increase up to 
100 fold more than normal levels when responding to an activating stimulus, such as a 
pathogen or, in our case, tissue damage.  
 There are four ways to measure cytokine changes following TBI: in blood, cerebrospinal 
fluid (CSF), microdialysis, and biopsy of brain tissue. Taking measurements from blood is the 
least invasive approach by measuring cytokine levels in plasma or serum. In cases of moderate 
to severe TBI’s, CSF that would normally be discarded while attempting to lower the intracranial 
pressure is saved for biomarker assays. During microdialysis, cerebral probes can be surgically 
implanted and measure local levels of cytokines (7). 
 The majority of studies on cytokine levels following TBI’s has been done with moderate 
to severe TBI’s, but recently a study was done on military personal who suffered TBI’s showing 
that an elevation in interleukin IL-6 and tumor necrosis factor α (TNFα) in plasma were 
associated with post-traumatic stress disorder (PTSD) and depression (28).  In this study, 83 
participants, who were all deployed the same time span 16 months previously, were given a 
Warrior Administered Retrospective Casualty Assessment Tool (WARCAT) and self-reported 
PTSD, depression, and quality of life assessments. The WARCAT was used as a self-reporting 
tool to assess post deployment and war-related TBI’s. Out of the 83 participants, 20 who self-
reported no TBI’s were used as the control and the remaining 63 were used as the TBI group. 
PTSD was measured using a PTSD military checklist that scores 0-80 with high scores correlating 
to increased severity. 
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Figure 5: Differences in plasma cytokine levels. Significant differences were found in IL-6 and 
TNF-α (a and d) but not for IL-10 or IL-6/IL-10 Ratios (b and c). TBI, Traumatic Brain Injury; TNF, 
tumor necrosis factor; IL, interleukin (28). 
 
Scores over 50 were identified as being PTSD positive participants. Depression was measured 
by using the Quick Inventory of Depressive Symptomatology (QIDS), scoring symptoms from 0 
to 7, with higher scores indicating increased severity. Participants with total scores over 13 
were considered to have depression (29). More information on the QIDS can be seen in the 
supplementary materials. WARCAT scores for the TBI participant group averaged 48.7, whereas 
the non-TBI group averaged a lower 32.5. A similar trend was seen with the QIDS scores as well 
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with the TBI group having an average score of 12.4 and the non-TBI average score being 7.7 
(28).  Plasma samples were then taken from the participants, centrifuged frozen at −80 °C, and 
then thawed and analyzed for cytokines as a single batch, results appear in Figure 5. 
 As Figure 5 shows, IL-6 and TNF-α levels are shown to be significantly elevated in 
participants who suffered TBI versus the non-TBI participants. IL-6 and TNF-α are known pro-
inflammatory cytokines and IL-10 is an anti-inflammatory cytokine, as stated earlier the pro-
inflammatory cytokines are associated with increased PTSD and depression symptoms.  
Below, in Figure 6, are the levels of cytokines in participants who are a part of the TBI group and 
determined to be either low-PTSD and QIDS scores or high-PTSD and QIDS scores. Even within 
the TBI participant group, significant differences appear again between IL-6 and TNF-α pro-
inflammatory cytokines being most elevated in the high PTSD and QIDS score group.  
 These results not only show that TBI relates to elevated pro-inflammatory cytokines, but 
also that high levels of pro-inflammatory cytokines relate with elevated PTSD and comorbid 
depression (28). Another significant finding of this study is the illustration of elevated cytokine 
levels months after the occurrence of TBI, which shows that there can be chronic elevation of 
cytokines and inflammation after TBI. 
 The evidence supporting the inflammatory theory of depression is correlative and relies 
of the presence of cytokines elevated in the blood or CSF of depressed individuals compared to 
healthy controls (7). A meta-analysis of 82 studies showed that peripheral levels of cytokines 
and chemokines, including IL-6 and TNF-α, were elevated in individuals with major depressive 
disorders compared to a healthy control (43). Another analysis furthered showed a correlation 
between cytokine levels and depression in that they found that cytokine levels decreased after 
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the implementation of anti-depression medication (43). 
 
Figure 6: Comparison of cytokine levels in military personnel who suffered TBI’s and have 
been diagnosed with low PTSD (N=35) and high PTSD (N=28). Significant differences were 
found for IL-6 and TNF-α (a-d) but not for IL-6 or IL-6/IL-10 ratios (b and c) (28). 
TBI, Traumatic Brain Injury; TNF, tumor necrosis factor; IL, interleukin.  
 
Also, when interferon cytokines are used as a treatment for hepatitis and multiple sclerosis, 
there is a strong association with the development of depression, with up to 80% of patients on 
type 1 interferon therapy developing depression (46).  Another link between cytokines and 
depression is that depression has seemed to be reduced when individuals have been treated 
with an anti-cytokine treatment compared to control groups. A review and meta-analysis of 16 
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studies showed a major reduction of depression symptoms compared to a placebo (49). 
   Cytokines play a major role in   Cytokines IL-1 and TNF-α directly play a role in 
serotonergic signaling (28). They have been shown regulate the serotonin transporter (SERT) by 
increasing the production of SERT and recruiting it to the membrane (28). SERT transports 
serotonin from the synapse back into the pre-synaptic neuron (10). Serotonin plays an 
important role in neuronal circuits, controlling mood and temperament (12).  This increase in 
SERT leads to the decrease of serotonin in the neuronal synapse, which has been shown to 
increase depression (12).   
In the hippocampus, TNF-α has significant effects on glutamate signaling by altering the 
expression, composition, and phosphorylation of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR), which effect duration of AMPAR-mediated 
spontaneous excitatory postsynaptic currents (8). Glutamate is an excitatory transmitter in the 
brain important for memory and learning. TNF-α effects on AMPAR activity appear to be 
concentration and exposure length dependent. An example of this is during an acute exogenous 
exposure of TNFα when an immediate increase in AMPAR surface expression and activity have 
been reported. In contrast, chronic exposure to low levels of TNFα, as in the case of normal 
aging, decreases AMPAR’s (8). TNF-α not only has an affect on excitatory neurotransmitters, 
but it also affects γ-aminobutyric acid (GABA) receptors. GABA is an inhibitory neurotransmitter 
in the brain that prevents stimulation by glutamate; this results in a calming sensation in the 
brain. Dysfunction of GABA receptors can play a role in psychiatric disorders and major 
depression (22). Specifically, TNFα acting on neurons causes a rapid internalization of GABAAR, 
which decreases its inhibitory synaptic strength (Pribiag and Stellwagen, 2013).  The effects 
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cytokines have on AMPAR and GABA receptors could potentially play a major role in the 
depressive symptoms following TBI and as seen in CTE.  
Behavioral Changes: 
 Behavioral changes in patients suffering from CTE are hard to assess and usually are 
reported post mortem by relatives of the patient. There have been many reports of this, but 
one of the most famous is of American football player Mike Webster. Mike Webster’s battle 
against CTE was made into a movie titled Concussion. He was the first individual to be 
diagnosed with CTE by Dr. Bennett Omalu in 2002 (38, 39). Family members reported impulsive 
aggression, rapid mood swings, and low interest in normal activities. These behaviors seemed 
unexplained until after Mike’s death in 2002. Now, and since, these behaviors and more have 
been deemed clinical symptoms of CTE. 
 Although no definite mechanism has been determined for these behavior changes, a 
possible explanation could be from the neuronal damage caused P-tau accumulation in mood 
controlling areas of the brain. These initial symptoms could be due to damage to the limbic 
system resulting in behavioral symptoms, such as emotional lability, aggression, and violence 
(13). Other factors could possibly be the accumulation of Lewy bodies in these same areas, as 
seen in study mentioned above. 
Memory Loss: 
Another symptom associated with CTE is memory loss. Temporary memory loss can be 
seen in patients instantly following TBI, but usually subsides after a few weeks (9). This can 
caused be intense inflammation, brain bleeds, or other damages resulting from the TBI. In CTE, 
memory loss is not instantaneous, as in some TBI’s, but slowly progresses over time.  
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Figure 7: Comparison of hippocampal pathology in two cases of moderate CTE. In example 1 
(a–f), there is a mild hippocampal atrophy, b mild neuronal loss in CA1, c sparse NFTs in CA1 d 
sparse NFTs in CA1, AT8 immunostain, e moderate numbers of diffusely immunopo- sitive AT8 
stained neurons in CA4, and f occasional AT8 immunopositive NFTs in the dentate gyrus. In 
example 2 (g–l), there is g more severe hippocampal atrophy, h clear neuronal loss in CA1, i 
moder- ate density of NFTs in CA1, Bielschowsky silver stain, j moderate density of NFTs in CA1, 
AT8 immunostain, k high numbers of AT8- stained neurons and NFTs in CA4, and l moderate 
numbers of AT8 immunopositive NFTs in the dentate gyrus (40). Bars indicate 100 μm.  
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This could possibly be explained by the mechanism of injury and how p-tau propagates through 
brain tissues. Location of beginning p-tau formation may be a significant aspect of the slow 
onset of symptoms presented by a patient. P-tau in stage one CTE patients is seen accumulated 
on the outer cortex of the brain (McKee). As stated above, excessive accumulation of p-tau 
causes neuronal dysfunction and death. Knowing that regions of the cerebral cortex are used 
for memory and learning, P-tau damage to these areas can cause memory loss. As time 
progresses, the P-tau migrates into deeper regions of the brain, causing atrophy to important 
memory related structures such as the hippocampus and amygdala. This is why more severe 
memory loss can be seen in patients that progress to a higher stage of diagnoses (Figure 7). 
 As stated in the previous section, glutamate is an important neurotransmitter 
associated with memory and learning. Additionally, the number of its receptors, AMPAR, can be 
reduced by TNF-α when expressed at chronic low levels (22). As seen in TBI’s, there is a chronic 
elevation of cytokines such as TNF- α above basal levels. Potentially, a long term elevation of 
TNF-α could be one reason why individuals with CTE have problems with memory and learning. 
Further, with CTE being a comorbid disease, other diseases such as Lewy body disease and 
Alzheimer’s disease could play a role in the degradation of memory. As seen above, Lewy 
Bodies are a possible source of the dementia symptoms demonstrated by CTE-LBD patients. 
Diagnosis:  
 Diagnosis of CTE so far has only been done post mortem in patients. The standard scale 
for the diagnosis of CTE was proposed in 2013 and staged CTE I through IV, with IV being most 
severe. In 2013, the neuro-pathological diagnosis of CTE were proposed, as follows:  
1. Perivascular foci of p-tau immunoreactive NFTs and ATs in the neocortex  
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2. Irregular distribution of p-tau immunoreactive NFTs and ATs at the depths of cerebral 
sulci  
3. NFTs in the cerebral cortex located preferentially in the superficial layers (often most 
pronounced in tem- portal cortex)  
4. Supportive, non-diagnostic features: Clusters of sub-pial ATs in the cerebral cortex, most 
pronounced at the sulcal depths. (3) 
Abbreviations: NFTs =Neurofibrillary tangles, ATs = astrocytic Tangles 
A study performed in March 2013 determined that the diagnostic neuropathological lesion of 
Chronic Traumatic Encephalopathy (CTE) was different from other taupathies. The 
pathognomonic lesion of CTE consists of p-tau aggregates in neurons, astrocytes, and cell 
processes around small vessels in an irregular pattern at the depths of the cortical sulci (Figure 
8) (3).   
 
Figure 8: Low magnification of phosphorylated tau (p-tau) stained slides showing the spatial 
pattern in CTE pathology in cortical sulci. Three different cerebral cortex slides from 3 separate 
CTE cases. The darker brown regions are areas of stained p-tau proteins (3). 
 It was also determined that the p-tau was detectible at a lower power than other 
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tauapathies and in an irregular pattern (3). This pattern consisted of astrocytic tangles, dot and 
thread like neurites located in the depths of sulci and along penetrating blood vessels.  This 
study also discovered that CTE wasn’t a single diagnosis, but is considered a co-morbid disease. 
Staging diagnosis for CTE was based of work from Braak and Braak who determined that there 
are 6 different stages based on characteristic distribution of NFT in patients who have AD. This 
staging system is the base of diagnosing AD used by the Nation Institute on Aging (3). The  
diagnostic stages of CTE are: 
 I: Brains that are in stage I show no gross anatomic or macroscopic differences 
 compared to normal brains. Microscopically, they show small isolated perivascular focal 
 epicenters of p-tau NFTs and neuropil neurites. These NFTs and neuropil neurites are 
 characterized as dot and thread like. Tau pathology is most commonly localized to the 
 depths of the cerebral sulci of the frontal, temporal, insular, septal and parietal cortices, 
 although there may also be sparse NFT scattered throughout the adjacent cortex. 
 II: Subtle macroscopic changes within the brain may occur in Stage II. This could be mild 
 enlargement of the frontal horns of the lateral ventricles and third ventricle; cavum 
 septum pellucidum and the locus coeruleus and substantia nigra may also become pale. 
 Multiple epicenters of p-tau will be found in the cortices and AT are seen in sub-pial 
 regions. In cortexes adjacent to p-tau epicenters, NFT are seen throughout cerebral 
 layers.  
 III: The majority of brains in stage III have macroscopic changes but little anatomical 
 change. Usually, there is a reduction in brain weight, mild atrophy of the temporal and 
 frontal lobes, and enlargement of the lateral and third ventricles. Also, atrophy is seen in 
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 the mammillary bodies, thalamus, and hypothalamus, as well as the corpus callosum 
 becoming thin. Half of subjects have septal abnormalities. The cavum septum 
 pellucidum and locus coeruleus become pale. Microscopically, patches of merging NFT, 
 NT’s, and AT are found around blood vessels in sulcal depths and in superficial laminae 
 of the cortex. NFT can be seen in the olfactory bulb, hippocampus, entorhinal cortex, 
 amygdala, hypothalamus, mammillary bodies, nucleus basalis of Meynert, substantia 
 nigra, dorsal and median raphe nuclei, and locus coeruleus. Neurofibrillary degeneration 
 of the hippocampus can be seen.  
 IV: Stage IV CTE brains show substantial decrease in brain weight with pronounced 
 atrophy of cerebrum, frontal and temporal lobes, medial temporal lobes, mammillary 
 bodies, and thalamus. Wide spread atrophy of white matter can be seen. Thinning of 
 corpus  callosum and hypothalamic floor are common. Septum abnormalities can be 
 seen, including cavum septum, perforations, fenestrations or total absence of the 
 posterior septum. The cavum septum pellucidum and locus coeruleus are pale. 
 Microscopically, diffuse myelin loss, astrocytosis of the white matter, and neuronal loss 
 in the cerebral cortex, hippocampus and substantia nigra occur. P-tau pathology is 
 densely distributed throughout the cerebrum, thalamus, hypothalamus, mammillary 
 bodies, basal ganglia,  brainstem, cerebellar dentate nucleus, and, occasionally, spinal 
 cord. The visual cortex is usually a spared area in this disease. NFT, most of which are 
 extracellular, are found throughout the hippocampal formation, including the dentate 
 gyrus.  Severe neuronal occurs loss in the hippocampus. There is marked loss of 
 myelinated nerve fibers, axonal dystrophy and loss throughout the cerebral and 
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 cerebellar white matter. 
 
 
 
Stage one (I) CTE 
 
Stage Four (IV) CTE  
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Figure 9: Comparison of stage I CTE  to stage IV CTE. Stage I shows small p-tau (brown spots) 
forming in the cortical sulci.  Stage IV illustrates widespread severe p-tau pathology, affecting 
most regions of the cerebral cortex and the medial temporal lobe but sparing the visual cortex 
in all but the most severe cases (40). 
Treatment: 
   With diagnosis of CTE being done post mortem, there is no definitive treatment at this 
time. Preventative measures while participating in contact sports or military related events can 
help avoid TBI’s. Wearing the correct protective equipment and avoiding unnecessary collisions 
or concussive blasts is the best way to avoid TBI’s. Also, athletes and military personnel should 
follow their organizations’ concussion protocols after experiencing a TBI to prevent further 
damage. Treatment of symptoms of CTE may be done to help improve quality of life of the 
patient. Studies have considered lowering depression symptoms by attempting to lower pro-
inflammatory cytokines in patients following a TBI. Blocking these signals could prevent 
inflammation and excitatory damage to neurons caused by the dysregulation of the glutamate 
and GABA signaling (7). Treatments with cytokine inhibitors has been shown to promote 
functional recovery in learning and memory tasks in TBI mouse models when implemented one 
week after sustaining the injury (35). Experiments have also shown that, following a TBI, neuro 
stem cells (NSC) may help in a regenerative process of the brain (35). This has sparked the 
interest of researchers to see if stem cell implementation could possibly be used as treatment 
method. Two methods of stem cell treatment are currently being investigated. The first is the 
modulation of naturally occurring endogenous NSC reservoirs within the patient and the second 
is implanting exogenous NSC into the patient to assist regeneration (35). Both methods have 
shown positive results in treatment of TBI’s in animal models but the human neurogenesis 
process is still unclear. A potential issue with this treatment process is that areas where a TBI 
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occurred may be to severely damaged and too hostile for the transplanted NSC to survive (35). 
Further, generation of sufficient functional NSC to be implanted has been proven difficult to do. 
Treatments adding Omega-3 fatty acids to a person’s diet has also shown to help combat TBI 
symptoms (50). Omega-3 fatty acids have been shown to help with neuro-synaptic transmission 
and improving neuroplasticity. Other possible treatments like behavioral therapy and memory 
exercises can also help deal with symptomatic mood swings and difficulty with recall.  
Conclusion: 
Limitations: 
 With the brain being encased in the skull, it is difficult to study without its removal. This 
is the most significant limitation encountered while researching CTE; it limits the number of 
participants available for studies. Additionally, with CTE only being heavily researched in recent 
years, little information of the living history of the patients used in most of these studies exists. 
Knowledge of the p-tau mechanism also remains incomplete, which makes it difficult when 
trying to create a treatment to inhibit its toxicity. The majority of the studies that have shown 
cytokine changes in individuals following TBI have been done in patients who have suffered a 
moderate to severe TBI. There has been limited data from individuals who suffer from mild TBI. 
Further, few studies have been done longitudinally for cytokine biomarkers within the blood or 
CSF. Knowing how long cytokines last and when possible increase may occur in the body could 
help prevent chronic inflammation in the brain.  
Future Research: 
 Future research in this field could occur in a wide range of areas. The most demanding 
areas of concern would be diagnosis of CTE in patients who are still living. A current study, 
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started in 2014, named Understanding Neurological Injuries and Traumatic Encephalopathy 
(UNITE), is working towards this. Their goal is to find associations in living patients at risk of CTE 
that can be then confirmed postmortem. Their hope is that this information could be used for 
further clinical diagnoses of CTE. Also, there are studies trying to solve this issue by tagging the 
p-tau protein with a marker that can be seen by Positron emissions testing (PET) scans. These 
studies hope that early diagnoses of the disease can be achieved through observing the 
accumulation and binding patterns of these P-tau proteins. Currently, the mechanism of neuro 
toxic p-tau is little understood. Further research needs to be done in order to understand the 
full pathogenesis of the toxic proteins and ways to prevent its propagation in CTE. Another 
future field of experiments is looking at biomarkers such as elevated levels of P-tau and 
cytokines in CSF. This information could also be used to help in early diagnosis. Over the past 
decade, a lot of information and associations have been discovered involving this disease, but 
funding and future discoveries are needed in hopes of finding a cure.  
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